Novanta Inc

Novanta, Inc. (NOVT) provides precision technology solutions for medical and advanced industrial applications. The company reported improving demand across robotics, medical technologies, semiconductor equipment, and AI-related applications, prompting management to raise its revenue outlook. Bookings increased 37% year-over-year, reinforcing confidence that organic growth is broadening across the portfolio. This strong performance and outlook support our positive view on Novanta's competitive position in the market.

Novanta, Inc. (NOVT) provides precision technology solutions for medical and advanced industrial applications. The company reported improving demand across robotics, medical technologies, semiconductor equipment, and AI-related applications, prompting management to raise its revenue outlook. Bookings increased 37% year-over-year, reinforcing confidence that organic growth is broadening across the portfolio. This strong performance and positive outlook highlight Novanta's competitive position in a growing market.

We initiated a position in Novanta Inc., a supplier of proprietary technology solutions and subsystems to medical and advanced industrial original equipment manufacturers. Novanta combines deep proprietary expertise (about 750 patents) in precision medicine, precision manufacturing, robotics and automation, and advanced surgery to solve complex technical challenges. Since 2012, Novanta has grown its revenues at a 12% CAGR and its EBITDA at 14%. Products are generally solely sourced during long design cycles in which Novanta acts as an extension of its customers’ R&D function, with very sticky revenue from designed-in positions spanning multiple years.

Novanta, Inc. (NOVT) underperformed due to underwhelming revenue growth and a subdued full-year cadence. Despite reporting 2Q25 results that exceeded 'Street' sales and EBITDA estimates, the stock faced selling pressure as subsequent results that beat on EPS were met with skepticism regarding near-term acceleration. The cautious positioning toward med-tech capital equipment and China-exposed components also weighed on sentiment during the quarter.

Novanta, Inc. (NOVT) underperformed due to underwhelming revenue growth and a subdued full-year cadence. Despite reporting results that exceeded 'Street' sales and EBITDA estimates, the stock faced selling pressure as subsequent results that beat on EPS were met with skepticism regarding near-term acceleration. The cautious positioning toward med-tech capital equipment and China-exposed components also weighed on sentiment during the quarter.